Professor Richard Wilson

Professor of Gastro-Intestinal Oncology (Clinical Research Gartnavel)

telephone: 01413303968
email: Richard.H.Wilson@glasgow.ac.uk

Biography

Richard Wilson graduated from Queen’s University Belfast in 1984 and then worked in N. Ireland and Scotland as a junior doctor in surgery which included three years of colorectal cancer laboratory research in QUB. He then trained in clinical oncology before undertaking a post-CCT Fellowship in the National Cancer Institute in the USA in medical oncology, phase I cancer trials and drug development.

He was appointed in 2001 as a Senior Lecturer in Queen's University Belfast and Consultant Oncologist in the Belfast City Hospital. He set up the first early phase cancer clinical trials programme on the island of Ireland, and was the first Clinical Director of the N. Ireland Cancer Trials Network. He was a member of both the Adjuvant and Advanced Disease subgroups and the main Colorectal Cancer Clinical Studies Group of the UK National Cancer Research Institute from 2002, and chaired the CSG from 2014 - 2017. He helped to set up the International Rare Cancer Initiative Small Bowel Adenocarcinoma Working Group in 2011 and is its Co-Chair and UK lead. He has been a member of the Medical Advisory Board for Bowel cancer Uk since 2013.

In 2019, he joined the Institute of Clinical Sciences in the University of Glasgow as Professor in Gastrointestinal Oncology and is an Honorary Consultant in Medical Oncology in the Beatson West of Scotland Cancer Centre.

His main interests are in gastrointestinal cancer (particularly in colorectal cancer but also small bowel and anal cancer and peritoneal malignancies), in drug development, biomarkers, personalised medicine and early and late phase clinical trials.

His work spans cancer biology, translational and clinical research, and he is committed to working with colleagues to bring cancer discovery science into the clinic. He is passionate about teaching students and training the next generation of cancer clinicians and researchers. He is the Glasgow Clinical Academic Training lead for the innovative TRACC programme in the Universities of Glasgow and Edinburgh which provides PhD positions for both postgraduate trainees and intercalating medical and dental students.

Publications

List by: Type | Date

Jump to: 2024 | 2023 | 2022 | 2021 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014

Number of items: 40.

2024

Shiu, K.-K. et al. (2024) NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer. 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, Chicago, Illinois, USA, 31 May-04 June 2024. (doi: 10.1200/jco.2024.42.17_suppl.lba3504)

2023

Murphy, M., McCaughan, E., Thompson, G., Carson, M. A., Hanna, J. R., Donovan, M., Wilson, R. H. and Fitzsimons, D. (2023) Trusting relationships between patients with non-curative cancer and healthcare professionals create ethical obstacles for informed consent in clinical trials: a grounded theory study. BMC Palliative Care, 22, 85. (doi: 10.1186/s12904-023-01204-6) (PMID:37393250) (PMCID:PMC10315048)

2022

El Helali, A. et al. (2022) A first-in-human Phase I dose-escalation trial of the novel therapeutic peptide, ALM201, demonstrates a favourable safety profile in unselected patients with ovarian cancer and other advanced solid tumours. British Journal of Cancer, 127(1), pp. 92-101. (doi: 10.1038/s41416-022-01780-z) (PMID:35568736)

Brown, L. C. et al. (2022) Experiences of running a stratified medicine adaptive platform trial: Challenges and lessons learned from 10 years of the FOCUS4 trial in metastatic colorectal cancer. Clinical Trials, 19(2), pp. 146-157. (doi: 10.1177/17407745211069879) (PMID:35083924) (PMCID:PMC9036145)

2021

Adams, R. A. et al. (2021) Capecitabine versus active monitoring in stable or responding metastatic colorectal cancer after 16 weeks of first-line therapy: results of the randomized FOCUS4-N trial. Journal of Clinical Oncology, 39(33), pp. 3693-3704. (doi: 10.1200/JCO.21.01436) (PMID:34516759)

Hanna, C. R. , Boyd, K. A. , Wincenciak, J. , Graham, J., Iveson, T., Jones, R. J. and Wilson, R. (2021) Do clinical trials change practice? A longitudinal, international assessment of colorectal cancer prescribing practices. Cancer Treatment and Research Communications, 28, 100445. (doi: 10.1016/j.ctarc.2021.100445) (PMID:34425469)

2019

Joharatnam-Hogan, N. et al. (2019) Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. Lancet Gastroenterology and Hepatology, 4(11), pp. 854-862. (doi: 10.1016/S2468-1253(19)30289-4) (PMID:31477558)

Salvucci, M. et al. (2019) A machine learning platform to optimize the translation of personalized network models to the clinic. JCO Clinical Cancer Informatics(3), pp. 1-17. (doi: 10.1200/CCI.18.00056) (PMID:30995124)

2018

Arkenau, H.-T. et al. (2018) An extended phase Ib study of epertinib, an orally active reversible dual EGFR/HER2 tyrosine kinase inhibitor, in patients with solid tumours. European Journal of Cancer, 103, pp. 17-23. (doi: 10.1016/j.ejca.2018.07.134) (PMID:30196106)

Basu, B. et al. (2018) Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer. Annals of Oncology, 29(9), pp. 1918-1925. (doi: 10.1093/annonc/mdy245) (PMID:30016392) (PMCID:PMC6158767)

Cross, W. et al. (2018) The evolutionary landscape of colorectal tumorigenesis. Nature Ecology and Evolution, 2(10), pp. 1661-1672. (doi: 10.1038/s41559-018-0642-z) (PMID:30177804) (PMCID:PMC6152905)

Allen, W. L. et al. (2018) Transcriptional subtyping and CD8 immunohistochemistry identifies patients with stage II and III colorectal cancer with poor prognosis who benefit from adjuvant chemotherapy. JCO Precision Oncology(2), pp. 1-15. (doi: 10.1200/PO.17.00241) (PMID:30088816) (PMCID:PMC6040635)

Woodcock, V. K. et al. (2018) A first-in-human phase I study to determine the maximum tolerated dose of the oral Src/ABL inhibitor AZD0424. British Journal of Cancer, 118(6), pp. 770-776. (doi: 10.1038/bjc.2017.484) (PMID:29438361) (PMCID:PMC5877436)

Adams, R. et al. (2018) Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial. Lancet Gastroenterology and Hepatology, 3(3), pp. 162-171. (doi: 10.1016/S2468-1253(17)30394-1) (PMID:29254887) (PMCID:PMC6125825)

2017

Lawler, M. et al. (2017) Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer. Gut, 67(1), pp. 179-193. (doi: 10.1136/gutjnl-2017-315333) (PMID:29233930) (PMCID:PMC5754857)

Lindner, A. U. et al. (2017) BCL-2 system analysis identifies high-risk colorectal cancer patients. Gut, 66(12), pp. 2141-2148. (doi: 10.1136/gutjnl-2016-312287) (PMID:27663504)

Schrock, A. B. et al. (2017) Genomic profiling of small-bowel adenocarcinoma. JAMA Oncology, 3(11), p. 1546. (doi: 10.1001/jamaoncol.2017.1051) (PMID:28617917) (PMCID:PMC5710195)

Alvi, M. A., Wilson, R. H. and Salto-Tellez, M. (2017) Rare cancers: the greatest inequality in cancer research and oncology treatment. British Journal of Cancer, 117(9), pp. 1255-1257. (doi: 10.1038/bjc.2017.321) (PMID:28934760) (PMCID:PMC5672935)

Alderdice, M. et al. (2017) Natural killer-like signature observed post therapy in locally advanced rectal cancer is a determinant of pathological response and improved survival. Modern Pathology, 30(9), pp. 1287-1298. (doi: 10.1038/modpathol.2017.47) (PMID:28621318)

Alvi, M. A. et al. (2017) Molecular profiling of signet ring cell colorectal cancer provides a strong rationale for genomic targeted and immune checkpoint inhibitor therapies. British Journal of Cancer, 117(2), pp. 203-209. (doi: 10.1038/bjc.2017.168) (PMID:28595259) (PMCID:PMC5520517)

Salvucci, M. et al. (2017) A stepwise integrated approach to personalized risk predictions in stage III colorectal cancer. Clinical Cancer Research, 23(5), pp. 1200-1212. (doi: 10.1158/1078-0432.CCR-16-1084) (PMID:27649552)

2016

Coyle, C. et al. (2016) ADD-ASPIRIN: A phase III, double-blind, placebo controlled, randomised trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common non-metastatic solid tumours. Contemporary Clinical Trials, 51, pp. 56-64. (doi: 10.1016/j.cct.2016.10.004) (PMID:27777129) (PMCID:PMC5127874)

Jamieson, D. et al. (2016) A phase I pharmacokinetic and pharmacodynamic study of the oral mitogen-activated protein kinase kinase (MEK) inhibitor, WX-554, in patients with advanced solid tumours. European Journal of Cancer, 68, pp. 1-10. (doi: 10.1016/j.ejca.2016.08.026) (PMID:27693888)

Graham, D. M., Coyle, V. M., Kennedy, R. D. and Wilson, R. H. (2016) Molecular subtypes and personalized therapy in metastatic colorectal cancer. Current Colorectal Cancer Reports, 12(3), pp. 141-150. (doi: 10.1007/s11888-016-0312-y) (PMID:27340376) (PMCID:PMC4879165)

ORIGIN Trial Investigators, (2016) Cardiovascular and other outcomes postintervention with insulin glargine and omega-3 fatty acids (ORIGINALE). Diabetes Care, 39(5), pp. 709-716. (doi: 10.2337/dc15-1676) (PMID:26681720)

Lawler, M. et al. (2016) Delivering a research-enabled multistakeholder partnership for enhanced patient care at a population level: The Northern Ireland Comprehensive Cancer Program. Cancer, 122(5), pp. 664-673. (doi: 10.1002/cncr.29814) (PMID:26695702) (PMCID:PMC4864440)

Pitsiladis, Y. P. et al. (2016) Athlome Project Consortium: a concerted effort to discover genomic and other “omic” markers of athletic performance. Physiological Genomics, 48(3), pp. 183-190. (doi: 10.1152/physiolgenomics.00105.2015) (PMID:26715623) (PMCID:PMC4773890)

Dunne, P.D. et al. (2016) EphA2 expression is a key driver of migration and invasion and a poor prognostic marker in colorectal cancer. Clinical Cancer Research, 22(1), pp. 230-242. (doi: 10.1158/1078-0432.CCR-15-0603) (PMID:26283684) (PMCID:PMC4694030)

2015

Lawler, M., Kaplan, R., Wilson, R.H. and Maughan, T. (2015) Changing the paradigm - multistage multiarm randomized trials and stratified cancer medicine. Oncologist, 20(8), pp. 849-851. (doi: 10.1634/theoncologist.2015-0014) (PMID:26070918) (PMCID:PMC4524758)

Alvi, M. A. et al. (2015) Comprehensive molecular pathology analysis of small bowel adenocarcinoma reveals novel targets with potential for clinical utility. Oncotarget, 6(25), pp. 20863-20874. (doi: 10.18632/oncotarget.4576) (PMID:26315110) (PMCID:PMC4673235)

Graham, D.M., Turkington, R.C., Salto-Tellez, M., Coyle, V.M. and Wilson, R.H. (2015) RE: Test of four colon cancer risk-scores in formalin fixed paraffin embedded microarray gene expression data. Journal of the National Cancer Institute, 107(5), djv055. (doi: 10.1093/jnci/djv055) (PMID:25758031)

Bogaerts, J. et al. (2015) Clinical trial designs for rare diseases: studies developed and discussed by the international rare cancers initiative. European Journal of Cancer, 51(3), pp. 271-281. (doi: 10.1016/j.ejca.2014.10.027) (PMID:25542058)

Wardle, S. L., Bailey, M. E. , Kilikevicius, A., Malkova, D. , Wilson, R. H. , Venckunas, T. and Moran, C. (2015) Plasma microRNA levels differ between endurance and strength athletes. PLoS ONE, 10(4), e0122107. (doi: 10.1371/journal.pone.0122107) (PMID:25881132) (PMCID:PMC4400105)

2014

Moreno Garcia, V. et al. (2014) Dose-response relationship in phase I clinical trials: a European Drug Development Network (EDDN) collaboration study. Clinical Cancer Research, 20(22), pp. 5663-5671. (doi: 10.1158/1078-0432.CCR-14-0719)

Andreyev, J. et al. (2014) Guidance on the management of diarrhoea during cancer chemotherapy. Lancet Oncology, 15(10), e447-e460. (doi: 10.1016/S1470-2045(14)70006-3) (PMID:25186048)

Wasan, H. et al. (2014) Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial. Lancet Oncology, 15(6), pp. 631-639. (doi: 10.1016/S1470-2045(14)70106-8) (PMID:24703531) (PMCID:PMC4012566)

Maughan, T.S. et al. (2014) A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? British Journal of Cancer, 110(9), pp. 2178-2186. (doi: 10.1038/bjc.2014.182) (PMID:24743706) (PMCID:PMC4007241)

Turkington, R.C., Purcell, C., James, C.R., Millar, J., Napier, E., Law, D., Gallagher, R., Morris, M., Wilson, R.H. and Eatock, M.M. (2014) A phase I trial of bortezomib in combination with epirubicin, carboplatin and capecitabine (ECarboX) in advanced oesophagogastric adenocarcinoma. Investigational New Drugs, 32(2), pp. 250-260. (doi: 10.1007/s10637-013-9970-7) (PMID:23665866)

Glasspool, R.M. et al. (2014) A randomised, phase II trial of the DNA-hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in combination with carboplatin vs carboplatin alone in patients with recurrent, partially platinum-sensitive ovarian cancer. British Journal of Cancer, 110(8), pp. 1923-1929. (doi: 10.1038/bjc.2014.116)

Jones, C., Badger, S. A., Stevenson, M., Diamond, T., McKie, L. D., Taylor, M. A., Wilson, R. H. and Lynch, T. B. (2014) PET-CT as a predictor of outcome in resectable colorectal liver metastases. European Journal of Gastroenterology and Hepatology, 26(4), pp. 466-472. (doi: 10.1097/MEG.0000000000000036) (PMID:24445726)

This list was generated on Thu Nov 21 22:09:42 2024 GMT.

Jump to: Articles | Conference or Workshop Item